Over 100 Years of Experience Spearheading the Development of Our Treatments

Leadership Team

HabibYacoub

Yacoub Habib, Ph.D, MBA

Chief Executive Officer and Chairman of the Board

Dr. Yacoub Habib, Ph.D., MBA, is the chief executive officer and Chairman of the Board for Ophidion, Inc. He has more than 25 years of senior executive experience in the pharmaceutical industry.

Dr. Habib most recently served as senior vice president, business development and corporate planning at Trevena, where he was since July 2015. Previously, from 2009 to June 2015, he served as vice president of business development at Ikaria, Inc. and led the business development strategy for the company until its acquisition by Mallinckrodt.

Julie Miwa1

Julie Miwa, Ph.D

Chief Scientific Officer

Julie Miwa, Ph.D, is Ophidion’s founder and chief scientific officer. Ophidion’s technology platform is based on Dr. Miwa’s science and understanding of complex neurobiological processes and how they are regulated through the cholinergic system. A key focus is on a class of modulators, lynx genes, which act as molecular brakes on the cholinergic system by binding to and inhibiting nicotinic acetylcholine receptors.

Douglas Greene1

Douglas Greene, MD

Chief Development Officer

Dr. Greene’s nearly 50 years of experience in biomedical research includes both a 30-year academic career in clinical and applied basic research as Director of the Clinical Research Center, Chairman of Endocrinology and Metabolism and Director of the Michigan Diabetes Research and Training Center at the University of Pennsylvania, University of Pittsburg and University of Michigan, followed by a 20-year career in leadership positions in the pharmaceutical industry as Head of Clinical Science & Product Development, Head of Regulatory Development, and Head of Research & Development at Merck, Sanofi-Aventis and Ikaria.

Douglas J. MacNeil1

Douglas J. MacNeil, Ph.D

VP of Preclinical Development

Dr. MacNeil has extensive experience in Early Drug Discovery and Development at major pharmaceutical companies. During his research career he rose from a bench level scientist to Director of In Vitro Sciences where he was responsible for in vitro assay support to over 40 research programs at Merck’s NJ research sites, many in the neurodegenerative space (including Alzheimer’s disease and Parkinson disease). He was a Team Lead or Biology Lead on multiple Drug Discovery and Development projects for obesity, hypertension, diabetes, NAFLD, Alzheimer’s disease, and Parkinson disease.

Joseph Hulihan1

Joe Hulihan, MD, MSHP

VP of Clinical Development

Dr. Hulihan is an Advisor for clinical development at Ophidion, with responsibility for research and development for all products and indications. He has formulated clinical plans and provided guidance on overall program design, clinical protocol development, and regulatory requirements for Ophidion programs.

Brigitte Angenieux1

Brigitte Angenieux, Ph.D

Executive Director of Preclinical Development

Dr. Angenieux is an executive director of preclinical development and has over fifteen years of experience in project management and research. This includes work in stem cells and cancer research, sterility assurance, bioassay and drug development in both academia and industry. She is currently the Executive Director of Preclinical Research.

Board of Directors

HabibYacoub

Yacoub Habib, Ph.D, MBA

Chief Executive Officer and Chairman of the Board

Dr. Yacoub Habib, Ph.D, MBA, is the chief executive officer and Chairman of the Board for Ophidion, Inc. He has more than 25 years of senior executive experience in the pharmaceutical industry.

Dr. Habib most recently served as senior vice president, business development and corporate planning at Trevena, where he was since July 2015. Previously, from 2009 to June 2015, he served as vice president of business development at Ikaria, Inc. and led the business development strategy for the company until its acquisition by Mallinckrodt.

fishman

Scott Fishman

Founder and CEO, Ethos LifeScience Advisors - Envisage

Scott Fishman has over 30 years of experience as a life science strategist across all sectors of the industry focusing on healthcare marketing research and commercial analysis. As CEO of Research by Design, a firm he started in 1989, Scott directed the evolution of the company from a bedroom startup to one of the most successful and prominent firms in the healthcare research industry.

Julie Miwa1

Julie Miwa, Ph.D

Chief Scientific Officer

Julie Miwa, Ph.D, is Ophidion’s founder and chief scientific officer. Ophidion’s technology platform is based on Dr. Miwa’s science and understanding of complex neurobiological processes and how they are regulated through the cholinergic system. A key focus is on a class of modulators, lynx genes, which act as molecular brakes on the cholinergic system by binding to and inhibiting nicotinic acetylcholine receptors.

Lark

Michael Lark, Ph.D

Independent Board Member

Dr. Lark has more than 30 years of experience at leading and managing drug discovery and development teams at both large pharmaceutical and small biotech companies. Mike is CSO at Mirata Pharmaceuticals, a pain therapeutics company focused on neuropathic pain and is an Entrepreneur in Residence at BioAdvance, an early stage venture capital firm.

New Project - 2022-05-14T102245.997

Claudine Buck, Ph.D

Independent Board Member

Dr Claudine Bruck is the CEO and co-founder of Prolifagen, a Start-Up company developing a microRNA-based drug for cardiac regeneration. She is also a course Director at University of Pennsylvania, at the
Institute of Translational Medicine and Applied Technology linked to the Perelman Medical School.
Dr Bruck serves on the Board of directors of 2 public Biotech companies.

Scientific Advisory Board

William-Yang

X. William Yang, M.D., Ph.D.

Dr. X. William Yang received his undergraduate education at Yale University, obtaining combined B.S./M.S. degrees from the Department of Molecular Biophysics & Biochemistry (MB&B) in 1991.

Andrew-Feigin

Andrew S. Feigin, M.D.

Dr. Feigin is the director of Experimental Therapeutics for Movement Disorders at the Feinstein Institute and director of the Huntington’s Disease Society of America Center of Excellence at North Shore University Hospital.

William-Yang

Christopher A Ross, M.D., Ph.D.

Professor at Johns Hopkins Medical School

Dr. Christopher Ross is a neuropsychiatry specialist in Baltimore, caring for patients with Huntington’s disease, movement disorders and neuropsychiatric complications of movement disorders. Dr. Ross serves as the Director of the Division of Neurobiology at the Johns Hopkins School of Medicine.